Persistent Increase in Plasma Thrombomodulin in Patients with a History of Lupus Nephritis: Endothelial Cell Activation Markers
Overview
Affiliations
Objective: To investigate the presence of continuing endothelial cell activation in patients with systemic lupus erythematosus (SLE) and its relationship with lupus nephritis.
Methods: We measured plasma concentrations of soluble thrombomodulin (sTM), vascular cellular adhesion molecule-1 (sVCAM-1), von Willebrand factor (vWf), sP-selectin, and ED1-fibronectin in 75 SLE patients with a median SLE disease activity index (SLEDAI) of 4. Forty patients with a history of lupus nephritis, confirmed by renal biopsy in 33, were compared with 35 patients without lupus nephritis and 25 controls. For subgroup analysis in patients with clinically stable remission we excluded patients with a SLEDAI > 6 or with evidence of renal disease activity.
Results: In the total SLE patient group sTM, sVCAM-1, vWf, and sP-selectin were significantly elevated compared with controls. In patients with a history of lupus nephritis plasma levels of sTM and vWf were significantly increased compared with SLE patients without nephritis. After adjustment for significantly associated variables, especially creatinine clearance and age, in a multivariate linear regression analysis, sTM remained significantly elevated in patients with a history of lupus nephritis (difference 28.9 ng/ml, 95% CI 11.5-46.4). In the subgroup analysis of 57 patients, the results remained unchanged.
Conclusion: The increase of sVCAM-1, sP-selectin, sTM, and vWf reflects a state of persistent endothelial cell activation. Multivariate regression analysis shows that the elevated sTM levels are strongly associated with a history of lupus nephritis, independent of creatinine clearance or disease activity, suggesting endothelial cell activation specifically localized in the kidneys.
Fawzy R, Serag M, Soliman A, Elwia S, Mojahed S Arch Rheumatol. 2023; 37(4):527-535.
PMID: 36879566 PMC: 9985374. DOI: 10.46497/ArchRheumatol.2022.9307.
PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus.
Li H, Meng D, Jia J, Wei H Lipids Health Dis. 2021; 20(1):95.
PMID: 34461924 PMC: 8404349. DOI: 10.1186/s12944-021-01515-8.
Plasma fibrinogen, D-dimer, and fibrin degradation product as biomarkers of rheumatoid arthritis.
Xue L, Tao L, Li X, Wang Y, Wang B, Zhang Y Sci Rep. 2021; 11(1):16903.
PMID: 34413382 PMC: 8377052. DOI: 10.1038/s41598-021-96349-w.
Qin L, Stanley S, Ding H, Zhang T, Truong V, Celhar T Arthritis Res Ther. 2019; 21(1):176.
PMID: 31319876 PMC: 6637532. DOI: 10.1186/s13075-019-1959-y.
Proulle V, Furie R, Merrill-Skoloff G, Furie B, Furie B Blood. 2014; 124(4):611-22.
PMID: 24825863 PMC: 4110663. DOI: 10.1182/blood-2014-02-554980.